多部位黏膜类天疱疮的位点特异性治疗与缓解模式
该单中心回顾性队列纳入77例多部位黏膜类天疱疮(MMP)患者,评估多部位完全缓解(mCR)及位点特异性治疗反应。
要点
- 多部位MMP中仅45%达到mCR,中位时间32.0个月。
- 口腔和眼部持续病变是阻碍mCR的主要部位。
- 位点完全缓解后44%复发,口腔和眼部最常见。
核心结论
- 多部位MMP患者中不足半数达到同时多部位缓解,尽管位点缓解率较高。
- 口腔和眼部持续病变不成比例地限制全局疾病控制,支持位点特异性疾病行为模型。
研究设计与样本
- 单中心回顾性队列研究,2013年1月1日至2025年1月1日于德克萨斯大学西南医学中心皮肤科和眼科转诊中心开展。
- 纳入经免疫病理确诊、累及2个及以上解剖部位且治疗后随访12个月的患者,共77例(55例女性,71%)。
- 诊断时中位年龄66岁(IQR 59-72)。
主要发现
- 68例(88%)为高危疾病,累及眼、喉、食管或肛门生殖器部位。
- 口腔病变最常见(73例,95%),其次为眼部(51例,66%)和鼻部(38例,49%)。
- 所有患者均有改善,64例(83%)在1个及以上位点达到完全缓解。
- 64例中28例(44%)在位点完全缓解后复发,最常见于口腔(18/28,64%)和眼黏膜(14/28,50%)。
关键数值与推荐
- mCR定义为所有受累部位同时完全缓解, regardless of therapy。
- 利妥昔单抗为基础方案和Janus激酶抑制剂治疗与高改善率相关。
- 严重不良事件最常发生于环磷酰胺单药和Janus激酶抑制剂治疗。
临床怎么用
- 临床评估多部位MMP时应关注位点特异性缓解,口腔和眼部持续病变常阻碍整体控制。
- 利妥昔单抗为基础方案和Janus激酶抑制剂与高改善率相关,但需注意严重不良事件。
- 环磷酰胺单药和Janus激酶抑制剂治疗时严重不良事件发生频率较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mucous membrane pemphigoid (MMP) is a chronic autoimmune blistering disease associated with progressive mucosal scarring and substantial morbidity. Prior studies have often reported remission rates in cohorts combining localized and multisite disease, with limited data on simultaneous remission across all involved sites in patients with multisite disease. OBJECTIVE: To evaluate multisite complete remission (mCR) and site-specific treatment response patterns in patients with multisite MMP. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study took place at a single tertiary dermatology and ophthalmology referral center at the University of Texas Southwestern Medical Center between January 1, 2013, and January 1, 2025. Patients with MMP confirmed by immunopathology, disease involving 2 or more anatomic sites, and 12 months posttreatment follow-up were included. MAIN OUTCOMES AND MEASURES: The primary outcome was mCR, defined as concurrent complete remission across all involved sites regardless of therapy. Secondary outcomes included site-specific remission and relapse patterns, time to remission, and treatment-associated adverse events. RESULTS: Among 77 patients (55 [71%] female; median [IQR] age at diagnosis, 66 [59-72] years), 68 (88%) had high-risk disease involving ocular, laryngeal, esophageal, or anogenital sites. Oral disease was most common, present in 73 patients (95%), followed by ocular disease in 51 (66%) and nasal disease in 38 (49%). Thirty-five patients (45%) achieved mCR in a median (IQR) of 32.0 (20.7-55.3) months. Although all patients demonstrated improvement and 64 (83%) achieved CR at 1 or more sites, persistent oral and ocular diseases frequently prevented mCR. Relapses following site-level CR occurred in 28 of the 64 patients (44%), most frequently at the oral (18 of 28 patients [64%]) and ocular mucosa (14 of 28 patients [50%]); some patients experienced relapse at multiple sites. Rituximab-based regimens and Janus kinase inhibitor therapy were associated with high rates of improvement. Serious adverse events occurred most frequently with cyclophosphamide monotherapy and Janus kinase inhibitor therapy. CONCLUSIONS AND RELEVANCE: In this cohort study, fewer than half of patients with multisite MMP achieved simultaneous multisite remission despite high rates of site-level response. Persistent oral and ocular diseases disproportionately limited global disease control, supporting a site-specific model of disease behavior and highlighting the need for standardized multisite remission outcomes in future studies.
引用
- McAleer L, La T, Li M, et al. Site-Specific Treatment and Remission Patterns in Multisite Mucous Membrane Pemphigoid. JAMA Dermatol. 2026. PMID: 42949703. doi:10.1001/jamadermatol.2026.4256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。